Sur ce site

Sur le Web du CNRS


Accueil du site > Productions scientifiques > Séminaires à PHENIX > 2012 > Séminaire 17.09.2012 à 11h00

Séminaire 17.09.2012 à 11h00

par Benjamin Rotenberg - 3 septembre 2012

Norbert Lange, de l’Université de Genève, présentera un séminaire le 17 septembre 2012 à 11h00 dans la bibliothèque du laboratoire PECSA (7e étage, bâtiment F, porte 754) intitulé :

The dark side of biophotonics : From Kings, Vampires, Sepia and Cancer


The introduction of lipophilic derivatives of the naturally occurring hème precursor 5-aminolevulinic acid (5-ALA) into photomedicine, has led to a true revival in this research area. 5-ALA-mediated photodynamic therapy (PDT) and fluorescence photodetection (FD) of neoplastic disease is probably one of the most selective cancer treatments currently known in oncology. Until today, this method has been assessed experimentally for the treatment of various medical indications. However, the limited local bioavailability of 5-ALA has widely hampered its access to daily clinical practice until today. Here, I aim at presenting the fundamental concepts underlying the use of 5 ALA in PDT and FD from a chemical, biochemical and pharmaceutical point of view. Then, experimental evidences from preclinical data of the improvements and limits observed with 5-ALA derivatives will be presented. The state-of-the art from clinical studies with 5-ALA esters will be discussed whereby special emphasis will be placed on the process that led to the development of HAL for the improved detection of bladder cancer.